Results 61 to 70 of about 13,154 (163)

Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil

Microbiology and Immunology, Volume 70, Issue 5, Page 261-267, May 2026.
ABSTRACT Hypervirulent Klebsiella pneumoniae (hvKp) has emerged globally as a major public health concern, often associated with severe community‐acquired and healthcare‐associated human infections. Despite alerts from PAHO/WHO on convergent hvKp strains with multidrug resistance in Latin America, comprehensive data from Brazil, the region's largest ...
Carlos Henrique Camargo, Ana Beatriz Nascimento Costa, Amanda Yaeko Yamada, Daniel de Sena Miranda, Pedro Smith Pereira Ferraro, Andreia Rodrigues de Souza, Amanda Maria de Jesus Bertani, Karoline Rodrigues Campos, Marlon Benedito Nascimento Santos, Rafaela Mastrangelo Rissetti, Carolina Lechinski de Paula, Patrik Júnior de Lima Paz, Maria Solange Duarte Soares, Christiane Salvador, Giovanna de Pinho Pieri, Jorge Siguemassa Higa, Daniela dos Santos Souza, Márcio Garcia Ribeiro, Claudio Tavares Sacchi, Monique Ribeiro Tiba‐Casas, Geraldine Madalosso, Denise Brandao de Assis   +21 more
wiley   +1 more source

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, Volume 16, Issue 4, Page 751-765, April 2026.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

An Unusual Case of Citrobacter koseri Infection During Pregnancy at 27 Weeks: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza, Michele Caramia, Jacopo Wabersich   +2 more
wiley   +1 more source

Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department [PDF]

, 2018
Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy. Methods: UTI cases
Bischoff, Sebastian, Ebert, Matthias, Gerigk, Marlis, Vogelmann, Roger, Walter, Thomas   +4 more
core   +1 more source

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +1 more source

Clinical Outcome Associated With Beta‐Lactam Allergy Labels in Hospitalized Patients in Belgium

Clinical and Translational Allergy, Volume 16, Issue 4, April 2026.
ABSTRACT Background In the United States, beta‐lactam allergy labels (BLAL) are documented in 9%–16% of hospitalized patients and associated with worse clinical outcomes such as increased mortality, length of hospital stay (LOS), intensive care unit (ICU) admission, and use of alternative antibiotics, providing an incentive for broad delabeling ...
Liesbeth Gilissen, Greet Van De Sijpe, Annouschka Laenen, Peter Declercq, Dries Wets, Ileana Ghiordanescu, Anca Mirela Chiriac, Willy E. Peetermans, Paul De Munter, Isabel Spriet, Rik Schrijvers   +10 more
wiley   +1 more source

Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae [PDF]

, 2017
The spread of carbapenemase-producing Klebsiella pneumoniae is a major public health concern since such isolates are basically resistant to most available antibiotics, including β-lactams, fluoroquinolones and aminoglycosides.1 Infections due to ...
Dubois, Véronique, Jayol, Aurélie, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

Frontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang, Yun Han, Yinshan Wu, Feng Guo, Zhenwei Yu   +4 more
doaj   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

International Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source